NasdaqGS - Delayed Quote • USD
Galapagos NV (GLPG)
At close: May 7 at 4:00 PM EDT
Pre-Market: 7:58 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 5 | 5 |
| Avg. Estimate | -0.05 | -0.13 | -0.21 | -0.95 |
| Low Estimate | -0.29 | -0.35 | -0.96 | -2.97 |
| High Estimate | 0.2 | 0.02 | 1.61 | 0.27 |
| Year Ago EPS | 0.08 | 0.43 | 3.45 | -0.21 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 7 | 7 |
| Avg. Estimate | 69.3M | 69.7M | 298.8M | 281.36M |
| Low Estimate | 59.17M | 60.24M | 243.58M | 239.89M |
| High Estimate | 80.14M | 80.25M | 415.99M | 323.69M |
| Year Ago Sales | 158.4M | 114.33M | 842.85M | 298.8M |
| Sales Growth (year/est) | -56.20% | -39.00% | -64.50% | -5.80% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.74 | -0.67 | -1.27 | -0.14 |
| EPS Actual | 0.08 | 0.43 | 2.57 | 1.51 |
| Difference | 0.82 | 1.1 | 3.84 | 1.65 |
| Surprise % | 110.80% | 164.20% | 302.40% | 1,178.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.05 | -0.13 | -0.21 | -0.95 |
| 7 Days Ago | -0.08 | -0.06 | -0.7 | -1.28 |
| 30 Days Ago | -0.19 | -0.17 | -1.27 | -1.53 |
| 60 Days Ago | -0.19 | -0.17 | -1.75 | -2.06 |
| 90 Days Ago | -0.94 | -0.86 | -2.72 | -2.7 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 2 | -- | 3 | 2 |
| Up Last 30 Days | 2 | -- | 3 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | 2 | -- | -- |
Growth Estimates
| CURRENCY IN USD | GLPG | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -162.50% | -- | -- | 7.00% |
| Next Qtr. | -130.20% | -- | -- | 10.70% |
| Current Year | -106.10% | -- | -- | 4.50% |
| Next Year | -352.40% | -- | -- | 13.20% |
| Next 5 Years (per annum) | 47.44% | -- | -- | 10.91% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 4/22/2024 |
| Downgrade | B of A Securities: Neutral to Underperform | 4/1/2024 |
| Downgrade | B of A Securities: Neutral to Underperform | 3/28/2024 |
| Maintains | B of A Securities: Neutral to Neutral | 1/2/2024 |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 8/7/2023 |
| Reiterates | Morgan Stanley: Equal-Weight to Equal-Weight | 8/1/2023 |
Related Tickers
ASMB Assembly Biosciences, Inc.
12.62
-1.79%
NXTC NextCure, Inc.
1.5800
-4.24%
SPRO Spero Therapeutics, Inc.
1.6600
0.00%
ALGS Aligos Therapeutics, Inc.
0.7900
-2.47%
TIL Instil Bio, Inc.
11.25
-2.51%
TBPH Theravance Biopharma, Inc.
9.54
-0.63%
CLRB Cellectar Biosciences, Inc.
3.2900
-1.20%
EIGRQ Eiger BioPharmaceuticals, Inc.
2.4300
-6.54%
BBIO BridgeBio Pharma, Inc.
27.79
-1.07%
RARE Ultragenyx Pharmaceutical Inc.
41.96
-2.44%